Plain English Summary

A collaboration agreement between National Health Service England (NHSE) and the manufacturer Grail evaluates the clinical and economic performance of Grail’s Galleri blood test. This has the potential to identify cancer in individuals who do not have any symptoms.  EEPRU will provide independent input to ensure robust economic evidence is available for NHSE's funding decisions. This is regarding the test when results from randomised trial in asymptomatic individuals in primary care (GRAIL-009) become available.

Phase 1 of the research involves reviewing current evidence sources, identifying potential gaps and methods uncertainties, and proposing research activities for Phase 2. This includes:

• establishing economic evidence on the Galleri tests,

• identifying gaps in planned economic analysis, 

• proposing solutions for these gaps, 

• and defining projects for Phase 2.